Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer's disease.

ABSTRACT:

Background

Beta-synuclein (β-syn), measured at N-terminal epitopes, is an emerging cerebrospinal fluid (CSF) biomarker for synaptic degeneration in Alzheimer's disease (AD). Targeting the mid-region or C-terminus of β-syn may enhance analytical specificity due to the distinct structures of these regions across the synuclein protein family, unlike targeting the N-terminus, which is conserved across the family. This study aimed to confirm that β-syn is a promising CSF biomarker in AD, using novel assays designed to target different regions of β-syn, to investigate whether these regions are differentially affected in AD.

Methods

We developed two novel CSF β-syn-specific ELISAs targeting mid-region and C-terminus epitopes and assessed their analytical performance. Using these no

SUBMITTER: Bayoumy S 

PROVIDER: S-EPMC11995646 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature